Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FinNissle randomized controlled trial preventing urinary tract infections in infants and young children
2026-526444-13-01Phase 3Authorised
- Sponsor
- Pohjois-Pohjanmaan hyvinvointialue
- Start
- Jul 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of escherichia coli nissle 1917 in urinary tract infection (UTI) and pyelonephritis (2 arms), sponsored by Pohjois-Pohjanmaan hyvinvointialue. Primary endpoint: Proportion of children with recurrent UTI during 6‑month follow‑up. Planned start Jul 2026; status: authorised.
02
Drugs
escherichia coli nissle 1917
03
Conditions
urinary tract infection (UTI)pyelonephritis
Beyond the preview
Go deeper on 2026-526444-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526444-13-01.